CCT-251921

N/A

Report date: 2022/07/01 15:29:28
NME

Base Information

Drug NameCCT-251921
Drug Alias NameCCT-251921
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionCyclin-dependent kinase 8 inhibitorsCyclin-dependent kinase 19 inhibitors
TargetsCyclin-dependent kinase 8Cyclin-dependent kinase 19
Therapy Area/IndicationsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesMerck KGaA, Darmstadt, GermanyCancer Research UK
China Registration ClassN/A

Develop Information

Active CompaniesMerck KGaA, Darmstadt, GermanyCancer Research UK
Inactive CompaniesN/A
Active IndicationsNeoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A